Ela Medical and Medtronic settle patent litigation:
This article was originally published in Clinica
Ela Medical, Synthelabo's (France) pacemaker subsidiary, has settled a patent dispute with Medtronic (US). The agreement between the companies provides for cross-licensing of all existing patents covering cardiac stimulation devices. It also provides for an undisclosed cash payment by Ela Medical to Medtronic. The Minneapolis-based company filed an action against Ela Medical for patent infringement in April 1994, against which Ela countersued.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.